ArticleJournal of geriatric cardiology : JGC2026
Semaglutide ameliorates coronary microembolization-induced injury by suppressing apoptosis and inflammation via the HMGB1/RAGE/NF-κB p65 pathway.
Article in Journal of geriatric cardiology : JGC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronary microembolization (CME) is the major leading cause of perioperative myocardial injury during coronary revascularization. Semaglutide exerts multiple protective biological activities, but its cardioprotective effects on CME remain unclear. Thus, this experiment studied the impact of semaglutide on CME-induced myocardial injury.
methodsA rat CME model was generated by injecting microspheres into the left ventricle while clamping the ascending aorta. A H9c2 cardiomyocyte model was constructed by stimulation of lipopolysaccharide combined with hypoxia. Semaglutide or the high mobility group box 1 (HMGB1) antagonist glycyrrhizin administrations were ahead of CME and cell modeling. Cardiac function, myocardial injury markers, cell viability and morphological alternations were detected. Apoptotic and inflammatory factors, cytosolic HMGB1 and its translocation, advanced glycosylation end-product specific receptor (RAGE), and nuclear factor kappa B p65 (NF-κB p65) were evaluated.
resultsSemaglutide pretreatment ameliorated CME-induced cardiac systolic dysfunction and relieved the cardiac injury. Semaglutide attenuated myocardial apoptosis and inflammatory response following CME
conclusionsSemaglutide pretreatment attenuates CME-induced myocardial injury by suppressing apoptosis and inflammation through the HMGB1/RAGE/NF-κB p65 pathway.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.